Targeted nanoparticle therapy for drug-resistant glioblastoma
Tumor targeted drug delivery nanoplatform to overcome therapy resistance glioblastoma
['FUNDING_R01'] · MAYO CLINIC JACKSONVILLE · NIH-11248014
A tumor-targeted nanoparticle that delivers a new NRP1-blocking drug plus everolimus for people with glioblastoma that does not respond to standard treatment.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC JACKSONVILLE (nih funded) |
| Locations | 1 site (JACKSONVILLE, UNITED STATES) |
| Trial ID | NIH-11248014 on ClinicalTrials.gov |
What this research studies
Researchers are developing a liposomal nanoparticle that carries a new, more soluble NRP1 inhibitor together with everolimus to reach glioblastoma cells and bypass the blood–brain barrier. The team is optimizing the drug formulation for stability and delivery so it can be stored and given reliably. Preclinical tests use patient-derived tumor cells and mouse models to check if the combination reduces therapy-resistant tumor-initiating cells and restores sensitivity to temozolomide. The long-term goal is to create a therapy that could be offered to people with recurrent, treatment-resistant GBM.
Who could benefit from this research
Good fit: People with recurrent or temozolomide-resistant glioblastoma, especially tumors showing NRP1-related biology, would be the most likely candidates.
Not a fit: Patients with non-glioblastoma brain tumors or whose disease is well controlled by standard treatments are unlikely to benefit from this work.
Why it matters
Potential benefit: If successful, this approach could make resistant glioblastoma more responsive to treatment and help extend patients' survival.
How similar studies have performed: Preclinical work showed that blocking NRP1 improved survival in mice and a first-generation liposomal combo helped resistant glioma cells, but this new, more soluble inhibitor and stable formulation are novel.
Where this research is happening
JACKSONVILLE, UNITED STATES
- MAYO CLINIC JACKSONVILLE — JACKSONVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MUKHOPADHYAY, DEBABRATA — MAYO CLINIC JACKSONVILLE
- Study coordinator: MUKHOPADHYAY, DEBABRATA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Brain Cancer